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Abstract
Dynamic treatment regimes operationalize the clinical decision process as a sequence of functions, one
for each clinical decision, where each function takes as input up-to-date patient information and gives
as output a single recommended treatment. Current methods for estimating optimal dynamic treatment
regimes, for example Q-learning, require the specification of a single outcome by which the ‘goodness’
of competing dynamic treatment regimes are measured. However, this is an over-simplification of the
goal of clinical decision making, which aims to balance several potentially competing outcomes. For
example, often a balance must be struck between treatment effectiveness and side-effect burden. We
propose a method for constructing dynamic treatment regimes that accommodates competing outcomes
by recommending sets of treatments at each decision point. Formally, we construct a sequence of set-
valued functions that take as input up-to-date patient information and give as output a recommended
subset of the possible treatments. For a given patient history, the recommended set of treatments contains
all treatments that are not inferior according to any of the competing outcomes. When there is more
than one decision point, constructing these set-valued functions requires solving a non-trivial enumeration
problem. We offer an exact enumeration algorithm by recasting the problem as a linear mixed integer
program. The proposed methods are illustrated using data from a depression study and from the CATIE
schizophrenia study.
1 Introduction
Dynamic treatment regimes (DTRs) attempt to operationalize the clinical decision-making process wherein
a clinician selects a treatment based on current patient characteristics and then continues to adjust treat-
ment over time in response to the evolving heath status of the patient. Formally, a DTR is a sequence
of decision rules, one for each decision point, that take as input current patient information and give as
output a recommended treatment. There is a growing interest in estimating the DTRs from randomized or
observational data, typically with the goal of finding the DTR that maximizes the expectation of a chosen
clinical outcome. A DTR is said to be optimal if when followed by the population of interest it produces
the maximal clinical outcome on average. Optimal DTRs have been estimated for the management of a
number of chronic conditions including ADHD [Laber et al., 2011, Nahum-Shani et al., 2010, 2012], depres-
sion [Schulte et al., 2012, Song et al., 2012], HIV infection [Moodie et al., 2007], schizophrenia [Shortreed
et al., 2011], and cigarette addiction [Strecher et al., 2006]. Approaches for estimating optimal DTRs from
data include Q-learning [Nahum-Shani et al., 2010, Watkins, 1989, Watkins and Dayan, 1992], A-learning
[Blatt et al., 2004, Murphy, 2003], regret regression [Henderson et al., 2010], and direct value maximization
[Orellana et al., 2010, Zhang et al., 2012, Zhao et al., 2012].
When estimating a decision rule from data using any of the aforementioned methods, one must specify
a single outcome and neglect all others. Perhaps the most obvious example is seeking the most effective
DTR without regard for side-effects. Alternatively, one might attempt to form a linear combination of
two outcomes, e.g. side effects and effectiveness, yielding a single composite outcome. However, forming a
composite outcome requires the elicitation of a trade-off between two potentially incomparable outcomes. For
example, one would need to know that a gain of 1 unit of effectiveness is worth a cost of 3 units of side-effects.
Even if one could elicit this trade-off at an aggregate level, assuming that a particular trade-off holds for
all future decision-makers is not reasonable since each will have his or her own individual preferences which
obviously cannot be known a priori. Lizotte et al. [2012] present one approach to dealing with this problem
using a method that estimates an optimal DTR for all possible linear trade-offs simultaneously. Their
method can also be used to explore what range of trade-offs is consistent with each available treatment.
Nonetheless, their method must assume that there exists a linear trade-off that adequately describes any
outcome preference, and they still (perhaps implicitly) require the elicitation of this trade-off.
We propose an alternative approach for constructing DTRs that is sensitive to competing outcomes but
that avoids eliciting trade-offs (linear or otherwise) between outcomes. Instead, our approach only requires
we elicit the size of a ‘clinically significant’ difference on each outcome scale. Our proposed method still
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allows for the incorporation of clinical judgement, individual patient preferences, cost, and local availability,
when no one treatment decision is best across all competing outcomes. Specifically, we propose set-valued
DTRs (SVDTRs) which, like DTRs, are a sequence of decision rules, one for each time point. However, the
decision rules that comprise a SVDTR take as input current patient information and give as output a set of
recommended treatments. The recommended treatment set will be a singleton when there exists a treatment
that is best across all outcomes and will contain multiple treatments when no single treatment is best.
The contributions of this paper are as follows. We introduce SVDTRs as a new method for operationaliz-
ing sequential clinical decision making that allows consideration of competing outcomes and the incorporation
of clinical judgment. SVDTRs deal with competing outcomes without having to elicit trade-offs between
competing outcomes — they only require the elicitation of what constitutes a clinically significant difference
for each outcome individually. We also provide a novel mathematical programming formulation which allows
us to efficiently estimate SVDTRs from data.
The remainder of this paper is organized as follows. In Section 2 we review the Q-learning algorithm for
estimating optimal DTRs from data. The Q-learning algorithm provides a starting point for the construction
of SVDTRs. In Section 3 we propose a SVDTR for the single decision point problem. We then extend this
methodology to the two decision point problem in Section 4, and in Section 4.1 we describe our mathematical
programming approach for the efficient estimation of SVDTRs from data. In Section 5 we illustrate the
construction of SVDTRs using data from a single decision depression trial [Keller et al., 2000] and a two-
stage schizophrenia study. For clarity, the main body of the paper considers only binary treatment decisions;
we give an extension to an arbitrary number of treatment options in the Appendix.
2 Single outcome decision rules
In this section we review the Q-learning algorithm for estimating an optimal DTR when there is a single
outcome of interest. For simplicity, we will consider the case in which there are two decision points and two
treatment options at each decision point. In this setting the data available to estimate an optimal DTR
are denoted by D = {(H1i, A1i, H2i, A2i, Yi)}ni=1 and consists of n trajectories (H1, A1, H2, A2, Y ), one for
each patient, drawn i.i.d. from some unknown distribution. We use capital letters like H1 and A1 to denote
random variables and lower case letters like h1 and a1 to denote realized values of these random variables.
The components of each trajectory are as follows: Ht ∈ Rpt denotes patient information collected prior
to the assignment of the tth treatment, thus, this is information the decision maker can use to inform the
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tth treatment decision; At ∈ {−1, 1} denotes the tth treatment assignment; Y ∈ R denotes the outcome
of interest which is assumed to be coded so that higher values are more desirable than lower values. The
outcome Y is commonly some measure of treatment effectiveness but could also be a composite measure
attempting to balance different objectives.
With a single outcome, the goal is to construct a pair of decision rules pi = (pi1, pi2) where pit(ht) denotes
a decision rule for assigning treatment at time t to a patient with history ht in such a way that the expected
response Y, given such treatment assignments, is maximized. Formally, if Epi denotes the joint expectation
over Ht, At, and Y under the restriction that At = pit(Ht), then the optimal decision rule pi
opt satisfies
EpioptY = suppi EpiY . Note that the optimal decision rule defined in this way ignores the impact of the DTR
piopt on any other outcomes not incorporated into Y .
One method for estimating an optimal DTR is the Q-learning algorithm [Watkins, 1989, Watkins and
Dayan, 1992]. Q-learning is an approximate dynamic programming procedure that relies on regression models
to approximate the following conditional expectations
Q2(h2, a2) , E(Y |H2 = h2, A2 = a2),
Q1(h1, a1) , E
(
max
a2∈{−1,1}
Q2(H2, a2)
∣∣H1 = h1, A1 = a1) .
The function Qt is termed the stage-t Q-function. The function Q2(h2, a2) measures the quality of assigning
treatment a2 at the second decision point to a patient with history h2. The function Q1(h1, a1) measures
the quality of assigning treatment a1 at the first decision point to a patient with history h1 assuming that an
optimal treatment decision will be made at the second decision point. From these definitions it is clear that
piopt2 (h2) = arg maxa2∈{−1,1}Q2(h2, a2), and, assuming that pi
opt
2 is followed at the second decision point,
piopt1 (h1) = arg maxa1∈{−1,1}Q1(h1, a1). Note that this is nothing more than the dynamic programming
solution to finding the optimal sequence of decision rules [Bellman, 1957].
In practice, the Q-functions are not known and so a natural approach is to estimate them from data.
As is common in practice, we will consider linear working models of the form Qt(ht, at) = h
ᵀ
t,1βt + ath
ᵀ
t,2ψt,
where ht,1 and ht,2 are (possibly the same) subvectors of ht. The Q-learning algorithm proceeds in three
steps:
1. Estimate the parameters indexing the working model for the stage-2 Q-function using least squares.
Let βˆ2 and ψˆ2 denote the corresponding estimators, and let Qˆ2(h2, a2) denote the fitted model.
2. (a) Define the predicted future outcome Y˜ following the estimated optimal decision rule at stage two
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as Y˜ , maxa2∈{−1,1} Qˆ2(H2, a2).
(b) Estimate the parameters indexing the working model for the stage-1 Q-function using least
squares. That is, regress Y˜ on H1 and A1 using the working model to obtain βˆ1 and ψˆ2. Let
Qˆ1(h1, a2) denote the fitted model.
3. Define theQ-learning estimated optimal treatment regime pˆi = (pˆi1, pˆi2) so that pˆit(ht) = arg maxat∈{−1,1} Qˆ(ht, at).
The Q-learning algorithm is simple to implement and easy to interpret given its connections to dynamic
programming. For these reasons we use Q-learning as the basis for developing SVDTRs which we introduce in
the next section. However, Q-learning is not the only procedure for estimating an optimal DTR. Alternatives
to Q-learning include A-learning [Blatt et al., 2004, Murphy, 2003, Schulte et al., 2012], regret regression
[Henderson et al., 2010], and penalized Q-learning [Song et al., 2012].
Penalized Q-learning also lends itself to producing SVDTRs, though of a different nature. Briefly, pe-
nalized Q-learning employs an unusual singular penalty to estimate the coefficients in the second stage
Q-function. For a given tuning parameter λ > 0 estimated coefficients β˜2 and ψ˜2 satisfy
(β˜ᵀ2 , ψ˜
ᵀ
2 )
ᵀ = arg min
β2,ψ2∈Rp2
n∑
i=1
(Yi −Hᵀ2,1,iβ2 −A2iHᵀ2,2,iψ2)2 + λ
n∑
i=1
|Hᵀ2,2,iψ2|.
Using this approach, under certain generative models, Hᵀ2,2ψ˜2 will be exactly zero for a non-null set of H2
values [see Song et al., 2012, for details]. One can then define the set-valued second stage decision rule
p˜i(h2) =
 {sgn(h
ᵀ
2,2ψ˜2)}, if hᵀ2,2ψ˜2 6= 0,
{−1, 1}, otherwise.
The foregoing set-valued decision rule assigns a single treatment for second stage histories h2 that, based on
the estimated coefficient ψ˜2 have a nonzero treatment effect. On the other hand, if the estimated treatment
effect hᵀ2,2ψ˜2 is zero, then both treatments are recommended. An analogous approach could be used to form
a set-valued decision rule at the first stage.
In the preceding development we have adapted the ideas of Song et al. [2012] to suit our purposes. They
proposed penalized Q-learning in an effort to improve coverage probabilities of confidence intervals for first
stage coefficients. Thus, any problems with this development are ours and should not be attributed to Song
et al. [2012]. Secondly, such set-valued treatment regimes attempt to recommend sets of treatment when
there is insufficient evidence of a significant treatment effect with respect to a single outcome measure for a
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patient with a given history. This should be contrasted with our goal of balancing the treatment effects of
competing outcomes.
3 Static set-valued decision rules
In this section we discuss the estimation of a set-valued decision rule when there is a single decision point and
there are two competing outcomes of interest (see the Appendix for the generalization to an arbitrary number
of treatment options). The data available to estimate the decision rule is denoted by D = {(Hi, Ai, Yi, Zi)}ni=1
and is comprised of n trajectories (H,A, Y, Z) drawn independently from the same distribution. The elements
of each trajectory are as follows: H denotes the information available to the decision maker before the
assignment of treatment and is assumed to take values in Rp; A denotes the randomly assigned treatment
which is assumed to be binary and coded to take values in the set {−1, 1}; Y denotes the first outcome of
interest which is assumed to take values in R and is coded so that higher values of Y correspond to more
desirable clinical outcomes; and Z denotes the second outcome of interest which is assumed to take values
in R and is also coded so that higher values are more desirable. It is also assumed that one has obtained,
either by elicitation or historical data, the positive quantities ∆Y and ∆Z denoting ‘clinically meaningful
differences’ in the outcomes Y and Z respectively. That is, a clinician would be willing to change a patient’s
current treatment if this change yielded a difference of at least ∆Y (∆Z) in the outcome Y (Z) and all other
things were held equal. Note that in eliciting ∆Y there is no need to reference the competing outcome Z
and vice versa when eliciting ∆Z .
The goal is to construct a decision rule pi : Rp → {{−1}, {1}, {−1, 1}} that maps baseline patient
information H into a subset of the available treatment decisions. Ideally, for a given baseline history h,
the decision rule pi would recommend a single treatment if that treatment was expected to yield a clinically
meaningful improvement in at least one of the outcomes and, in addition, that treatment was not expected
to lead to a significant detriment in terms of the other outcome. On the other hand, if this cannot be said of
one the treatments then the decision rule should instead return the set {−1, 1} and leave the ‘tie-breaking’ to
the decision maker. Put more formally, if we define the (non-normalized) treatment effects for each outcome
as rY (h) , E(Y |H = h,A = 1)−E(Y |H = h,A = −1) and similarly rZ(h) , E(Y |H = h,A = 1)−E(Y |H =
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∆Y−∆Y
∆Z
−∆Z
{−1, 1}
{−1, 1}
{−1, 1}
rZ(h)
rY (h)
{−1}
{1}
Figure 1: Diagram showing how the output of piIdeal(h) depends on ∆Y and ∆Z , and on the location of the
point (rY (h), rZ(h)).
h,A = −1), then the ideal decision rule satisfies
piIdeal∆ (h) =

{sgn(rY (h))}, if |rY (h)| ≥ ∆Y and sgn(rY (h))rZ(h) > −∆Z ,
{sgn(rZ(h))}, if |rZ(h)| ≥ ∆Z and sgn(rZ(h))rY (h) > −∆Y ,
{−1, 1}, otherwise,
(1)
where sgn denotes the signum function. Figure 1 illustrates how piIdeal∆ (h) depends on rY (h), rZ(h), ∆Y , and
∆Z . If we consider the point (rY (h), rZ(h)) ∈ R2, its location relative to the points (∆Y ,∆Z), (−∆Y ,∆Z),
(∆Y ,−∆Z) and (−∆Y ,−∆Z) determines whether we prefer treatment 1, prefer treatment −1, or are indif-
ferent according to the criteria set out above.
Following the motivation for Q-learning, we will estimate the ideal decision by modelling the conditional
expectations QY (h, a) , E(Y |H = h,A = a) and QZ(h, a) , E(Z|H = h,A = a). We will use linear working
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models of the form
QY (h, a) = h
ᵀ
1,1,Y βY + ah
ᵀ
1,2,Y ψY , (2)
QZ(h, a) = h
ᵀ
1,1,ZβZ + ah
ᵀ
1,2,ZψZ , (3)
where h1,1,Y , h1,2,Y , h1,1,Z , and h1,2,Z are (possibly the same) subvectors of h, and estimate the coefficients
βY , ψY , βZ , and ψZ using least squares. In the remainder of this Section, in an effort to avoid cumbersome
notation, we will assume hi,j,Z and hi,j,Y are equal and thus can be denoted as hi,j . This assumption is
only for notational efficiency and is not used in Section 5. Let βˆY , ψˆY , βˆZ , and ψˆZ denote the corresponding
least squares estimators. Note that the implied estimators of rY (h) and rZ(h) are 2h
ᵀ
2,1ψˆY and 2h
ᵀ
2,1ψˆZ
respectively. Hence, a simple plug-in estimator of the ideal decision rule is given by
pˆi∆(h) =

{sgn(hᵀ1,2ψˆY )}, if 2|hᵀ1,2ψˆY | ≥ ∆Y and sgn(hᵀ1,2ψˆY )2hᵀ1,2ψˆZ > −∆Z ,
{sgn(hᵀ1,2ψˆZ)}, if 2|hᵀ1,2ψˆZ | ≥ ∆Z and sgn(hᵀ1,2ψˆZ)2hᵀ1,2ψˆY > −∆Y ,
{−1, 1}, otherwise.
(4)
The above decision rule mimics the ideal decision rule and is easily shown to be consistent under mild
moment conditions and the assumption that the working models in (2) and (3) are correct. While the above
model is a compact representation of pˆi∆, it will often be convenient to display the decision rule either as a
tree or as regions in the hᵀ1,2ψˆY , h
ᵀ
1,2ψˆZ plane (see Section 5 for examples).
3.1 Preference heterogeneity and set-valued rules
Personalized medicine recognizes the need to account for heterogeneity in treatment effects across patients.
However, it is important to recognize not only that different patients will experience different outcomes under
the same treatments, but also that different patients will rate the same outcomes differently. In this section
we illustrate how set-valued decision rules can accommodate patient individual preference even though such
preferences cannot be known at the time the data are collected and the models are estimated. We contrast
set-valued decision rules with single outcome decision rules formed using a composite outcome. We shall see
that when the composite outcome closely reflects patient preferences then the corresponding decision rule
performs well, however, when the composite outcome does not reflect patient preferences, then the quality
of the single outcome decision rule can perform poorly.
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We will consider data generated from the following simple class of generative models
H = (H1, H2)
ᵀ ∼ Normal2 (0,Ω) ,
A ∼ Uniform{−1, 1},
Y = A(ψY,1 + ψY,2H1 + ψY,3H2 + ψY,4H1H2),
Z = A(ψZ,1 + ψZ,2H1 + ψZ,3H2 + ψZ,4H1H2),
where Ω1,1 = Ω2,2 = 1, and Ω1,2 = Ω1,2 = ρ. Thus, the class of models is determined by ψY , ψZ , ρ, and
the thresholds ∆Y and ∆Z . Note that we have omitted specifying a main-effect term in the conditional
mean of the outcomes Y and Z since these do not affect the optimal decision rule; similarly, we have
assumed that Y and Z are observed without error since an independent additive error would not affect
the optimal decision rule. We vary the parameters indexing the generative models in order to highlight
factors that affect the performance of the set-valued decision rule. In particular, we systematically vary the
following three components of the generative model: (i) the proportion of individuals for which there is a
unique best treatment option (Uniq); (ii) the proportion of individuals for which neither treatment yields a
significant treatment effect on either outcome (Null); and (iii) the proportion of individuals for which there
are significant treatment effects for both outcomes but the effects run in opposite directions (Opst). More
specifically, define
Uniq , P
({|rY (H)| ≥ ∆Y , sgn(rY (H))rZ(H) ≥ −∆Z}⋃{|rZ(H)| ≥ ∆Z , sgn(rZ(H))rY (H) ≥ −∆Y )});
Null , P
(
{|rY (H)| < ∆Y }
⋂
{|rZ(H)| < ∆Z}
)
; and
Opst , P (|rY (H)| ≥ ∆Y , |rZ(H)| ≥ ∆Z , rY (H)rZ(H) < 0) .
Note that Uniq, Null, Opst sum to one. The three settings for Uniq, Null, and Opst that we consider here
and the corresponding values of ψY , ψZ , ρ,∆Y , and ∆Z are given in Table 3.1.
Setting Uniq Null Opst ψY ψZ ρ ∆Y ∆Z
1 0.80 0.10 0.10 (−0.30, 0.25,−2.0) (0.0,−0.72,−0.74) −0.38 0.5 0.5
2 0.45 0.10 0.45 (−0.05, 0.40,−1.25) (0.65,−0.85, 0.29) −.36 0.5 0.5
3 0.10 0.10 0.80 (−1.0,−1.4, 2.0) (1.6, 2.2,−2.2) −0.4 0.5 1.0
Table 1: Settings for parameters indexing the underlying generative model. The settings vary from mostly
individuals with unique best treatments to mostly individuals with significant treatment effects running in
opposite directions.
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In this example, patient preference is operationalized through what we term the preference parameter
δ ∈ [0, 1], similar to the approach of Lizotte et al. [2012]. A preference of δ indicates that a patient would be
ambivalent between a one unit improvement (detriment) in Z and a δ/(1−δ) improvement (detriment) in Y .
For patients with preference parameter δ the optimal decision rule is given by pic,δ(h) , arg maxa E(δY +(1−
δ)Z|H = h,A = a); thus, the optimal composite outcome is given by δY + (1− δ)Z. Below we will compare
decision rules derived from the set-valued decision rule of the preceding section with pic,0.5 and pic,0.25.
For a patient’s ‘true preference’ δ∗ define the regret of an arbitrary decision rule pi as
E
[
E(δ∗Y + (1− δ∗)Z|H,A = pi(H))−max
a
E(δ∗Y + (1− δ∗)Z|H,A = a)
]
,
so that the regret measures the average loss in performance incurred by applying a suboptimal decision rule
pi. The regret is nonnegative and equals zero when pi agrees with the optimal decision rule, pic,δ∗ , almost
surely.
In order to define the regret for a set-valued decision rule one must specify a mechanism for choosing a
treatment from the set of recommended treatments. Here we consider two possible ‘tie-breaking’ scenarios.
In the first, we assume that the clinician will choose the best action from among the recommended treatments
with probability 0.75; we believe this reflects a clinicians ability to leverage individual patient characteristics
and preferences in the decision process. Recall that the set-valued decision rule provides not only the pool
of recommended treatments but also the estimated mean outcomes for each response; thus this information
can be used to inform the clinician’s decision. We term the resultant (random) decision rule the 75% optimal
compatible policy. In the second tie-breaking scenario we imagine an adversarial decision maker that always
chooses the worst of the available treatments. Such a decision maker was considered by Milani Fard and
Pineau [2011] in the study of non-deterministic decision rules for a single outcome. While a clinician that is
actively working against their patients is unrealistic, the performance of such a policy is useful for illustrating
the impact of screening out suboptimal treatments which occurs in the formation of the set-valued decision
rule. We term the resultant (deterministic) decision rule the 0% optimal compatible policy. To provide
additional baselines for comparison with the 75% and 0% optimal compatible polices, we also consider a
policy in which a clinician chooses the optimal treatment from among all possible treatments 75% of the
time and a policy in which the clinician always chooses the worst possible treatment from among all possible
treatments; we term these policies the 75% optimal policy and 0% optimal policy respectively.
Figure 3.1 compares the regret of composite-outcome based policies pic,0.5 and pic,0.25 with set-valued-
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Figure 2: Regret versus patient preference for the 75% and 0% consistent policies as well as pic,0.5 and pic,0.25.
The blue shaded region indicates the space of all policies that are compatible with the set-valued decision
rule. From left to right: parameter settings 1, 2, and 3.
policy-derived 75% and 0% optimal compatible policies across a range of patient preferences. When there is
a small fraction of individuals with significant treatment effects running in opposite directions (e.g., setting 1,
when Opst is small) then the composite outcome based policies perform well unless the preference is grossly
misspecified. However, when there is a moderate to large fraction of individuals with significant treatment
effects running in opposing directions (e.g., settings 2 and 3, when Opst is moderate and large) then using a
composite outcome based on only a slightly misspecified patient preference can lead to regrets near the 0%
optimal compatible policy! In contrast, the 75% optimal compatible policy remains relatively stable across
all three settings and all patient preferences even though no patient preference information is required to
estimate the set-valued decision rule. Figure 3.1 compares the regret of the 75% and 0% optimal policies with
the 75% and 0% optimal compatible policies. When there are many individuals with unique best treatments
(e.g., setting 1, when Uniq is large) then the set-valued decision rule screens many suboptimal treatments
and we see that the 75% optimal policy is dominated by the 0% optimal compatible policy. As there are
fewer individuals with unique optimal treatments the difference between the 75% optimal compatible and
75% optimal policies as well as the difference between the 0% optimal compatible and 0% optimal policies
converges to zero. The reason for this is clear, as there are a smaller number of unique best treatments fewer
suboptimal treatments are screened out.
4 Dynamic set-valued decision rules
In this section we extend set-valued decision rules to the case with two decision points and two compet-
ing outcomes. In order to make this extension we will need to generalize the notation from the previ-
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Figure 3: Regret versus patient preference for the 75% and 0% consistent policies as well as pic,0.5 and pic,0.25.
The blue shaded region indicates the space of all policies that are compatible with the set-valued decision
rule. From left to right: parameter settings 1, 2, and 3.
ous section. The data available estimate a pair of decision rules, one for each time point, is denoted by
D = {(H1,i, A1,i, H2,i, A2,i, Yi, Zi)}ni=1 and is comprised of trajectories (H1, A1, H2, A2, Y ) drawn indepen-
dently from a fixed but unknown distribution. The elements in each trajectory are as follows: Ht ∈ Rpt ,
t = 1, 2 denotes the patient information available to the decision maker before the tth decision point1;
At ∈ {−1, 1}, for t = 1, 2 denotes the randomly assigned treatment at the tth stage; Z, Y ∈ R denotes
competing outcomes observed sometime after the assignment of the second treatment A2. As in the previous
section, we assume that both Y and Z are coded so that higher values are preferred. Also available are the
quantities ∆Y and ∆Z denoting clinically relevant quantities for Y and Z respectively.
The goal is to construct a pair of decision rules pi = (pi1, pi2) where pit : Rpt → {{−1, 1}, {−1}, {1}}
maps up-to-date patient information to a subset of the possible decisions. Like the ideal static decision
rule considered in the previous section, for a patient with second stage history h2, the ideal second stage
decision rule, piIdeal2∆ , should recommend a single treatment if that treatment is expected to yield a clinically
meaningful improvement in one or both of the outcomes without leading to significant loss in either. Thus,
by straightforward extension of the notation for the static-decision case we have,
piIdeal2∆ (h2) =

{sgn(r2Y (h2))}, if |r2Y (h2)| ≥ ∆Y and sgn(r2Y (h2))r2Z(h2) > −∆Z ,
{sgn(r2Z(h2))}, if |r2Z(h2)| ≥ ∆Z and sgn(r2Z(h2))r2Y (h2) > −∆Y ,
{−1, 1}, otherwise,
(5)
where r2Y (h2) , E(Y |H2 = h2, A2 = 1) − E(Y |H2 = h2, A2 = −1) and similarly, r2Z(h2) , E(Z|H2 =
h2, A2 = 1)− E(Z|H2 = h2, A2 = −1).
1Note that H2 may contain some or all of the vector (A1, H
ᵀ
1 )
ᵀ.
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We now define piIdeal1∆ given that a clinician always selects treatments from the set-valued decision rule
piIdeal2∆ at the second stage. This problem is complicated by the fact that, unlike in the standard setting, there
exists a set of histories h2 at the second stage—those for which pi
Ideal
2∆ (h2) = {−1, 1}—where we do not know
the treatment that would be chosen. To address this, we begin by assuming we know that some particular
non-set-valued decision rule τ2 will be used at the second stage; we will then consider an appropriate set of
possible τ2 in order to define pi
Ideal
1∆ .
Suppose that a clinician uses the non-set-valued decision rule τ2 : Rp2 → {−1, 1} to assign treatments to
patients at the second decision point. That is, if a patient presents with history h2 then the clinician will
assign treatment τ2(h2). What is the ideal decision rule at the first decision point knowing that the clinician
is using τ2 to assign treatments at the second decision point? For any function τ2 : Rp2 → {−1, 1} define
Q2Y (h2, τ2) , E(Y |H2 = h2, A2 = τ2(h2)). Furthermore, define Q1Y (h1, a1, τ2) , E(Q2Y (H2, τ2)|H1 =
h1, A1 = 1) so that Q1Y (h1, a1, τ2) is the expected outcome for a patient with first stage history H1 = h1
treated at the first decision point with A1 = a1 and the decision rule τ2 at the second decision point.
Replacing Y with Z above gives the definitions of Q2Z(h2, τ2) and Q1Z(h1, a1, τ2). Thus, if it is known that
a clinician will follow τ2 at the second decision point, then the ideal decision rule at the first decision point
is given by
piIdeal1∆ (h1, τ2) =

{sgn(r1Y (h1, τ2))}, if |r1Y (h1, τ2)| ≥ ∆Y and sgn(r1Y (h1, τ2))r1Z(h1, τ2) > −∆Z ,
{sgn(r1Z(h1, τ2))}, if |r1Z(h1, τ2)| ≥ ∆Z and sgn(r1Z(h1, τ2))r1Y (h1, τ2) > −∆Y ,
{−1, 1}, otherwise,
(6)
where r1Y (h1, τ2) , Q1Y (h1, 1, τ2)−Q1Y (h1,−1, τ2), and similarly r1Z(h1, τ2) , Q1Z(h1, 1, τ2)−Q1Z(h1,−1, τ2).
Note that piIdeal1∆ (h2, τ2) assigns a single treatment if that treatment is expected to yield a clinically meaning-
ful improvement on one or both the outcomes while not causing clinically meaningful loss in either outcome
whilst accounting for the clinician’s behavior at the second decision point, assuming that behaviour is de-
scribed by the non-set-valued rule τ2.
We now describe how to construct the ideal decision rule at the first decision point when the rule at the
second decision point is set-valued. We say a non-set-valued rule τ2 is compatible with a set-valued decision
rule pi2 if and only if
τ2(h2) ∈ pi2(h2) ∀h2 ∈ Rp2 . (7)
Let C(piIdeal2∆ ) be the set of all rules that are compatible with piIdeal2∆ . We define piIdeal1∆ to be a set-valued
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decision rule
piIdeal1∆ (h1) =
⋃
τ∈C(piIdeal2∆ )
piIdeal1∆ (h1, τ). (8)
Our motivation for this definition is driven by a desire to maintain as much choice as possible at stage 1,
while making as few assumptions about future behaviour as possible. We assume only that in the future
some τ2 in accordance with pi2 will be followed. Therefore at stage 1 we only eliminate actions for which
there exists no compatible future decision rule that makes that action a desirable choice.
Note that if we do not assume a particular functional form for τ , the set C(piIdeal2∆ ) will be very large,
and computing the union (8) will be intractable. In practice, we will see that the modelling choices made
in order to estimate Q2Y and Q2Z suggest a reasonable subset of C(piIdeal2∆ ) over which we will take the
union (8) instead. We will provide a mathematical programming formulation that allows us to use existing
optimization algorithms to efficiently compute the union over this smaller subset.
We now turn to the estimation of piIdeal1∆ and pi
Ideal
2∆ from data. First, we note that to estimate the ideal
second decision rule we simply apply the results for the static set-valued decision rule developed in the
previous section. That is, we postulate linear models for second stage Q-functions, say, of the form
Q2Y (h2, a2) = h
ᵀ
2,1β2Y + a2h
ᵀ
2,2ψ2Y ,
Q2Z(h2, a2) = h
ᵀ
2,1β2Z + a2h
ᵀ
2,2ψ2Z ,
which we estimate using least squares. The estimated ideal second stage set-valued decision rule pˆi2∆ takes
the form given in (4). In order to estimate the ideal decision rule at the first decision point we must
characterize how a clinician might assign treatments at the second decision point. We make the assumption
that clinicians’ behavior, denoted τ2, is compatible with pˆi2∆ as defined in (20), and we assume that τ2 can be
expressed as a thresholded linear function of h2. We call such decision rules feasible for pˆi2∆, and we define
the set of feasible decision rules at stage 2 by
F(pˆi2∆) ,
{
τ2 : ∃ρ ∈ Rp2 s.t. τ2(h2) = sgn(hᵀ2,2ρ) and τ2 ∈ C(pˆi2∆)
}
.
Thus, F(pˆi2∆) denotes the collection of second stage non-set-valued decision rules that a clinician might
follow if they were presented with pˆi2∆. Note that F(pˆi2∆) is non-empty since sgn(hᵀ2,2( 12∆Y ψˆ2Y + 12∆Z ψˆ2Z))
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belongs to F(pˆi2∆). For an arbitrary τ2 ∈ F(pˆi2∆) define the working models
Q1Y (h1, a1, τ2) = h
ᵀ
1,1β1Y (τ2) + a1h
ᵀ
1,2ψ1Y (τ2),
Q1Z(h1, a1, τ2) = h
ᵀ
1,1β1Z(τ2) + a1h
ᵀ
1,2ψ1Z(τ2), (9)
where β1Y (τ2), ψ1Y (τ2), β1Z(τ2), and ψ1Z(τ2) are coefficient vectors specific to τ2. For a fixed τ2 one can
estimate these coefficients by regressing Qˆ2Y (H2, τ2) = H
ᵀ
2,1βˆ2Y +τ2(H2)H
ᵀ
2,2ψˆ2 and Qˆ2Z(H2, τ2) = H
ᵀ
2,1βˆ2Z+
τ2(H2)H
ᵀ
2,2ψˆ2Z on H1 and A1 using the working models in (9). Let Qˆ1Y (h1, a1, τ2) and Qˆ1Z(h1, a1, τ2) denote
these fitted models, and let rˆ1Y , Qˆ1Y (h1, 1, τ2)−Qˆ1Y (h1,−1, τ2), and rˆ1Z , Qˆ1Z(h1, 1, τ2)−Qˆ1Z(h1,−1, τ2).
We then define
pˆiIdeal1∆ (h1, τ2) =

{sgn(rˆ1Y (h1, τ2))}, if |rˆ1Y (h1, τ2)| ≥ ∆Y and sgn(rˆ1Y (h1, τ2))rˆ1Z(h1, τ2) > −∆Z ,
{sgn(rˆ1Z(h1, τ2))}, if |rˆ1Z(h1, τ2)| ≥ ∆Z and sgn(rˆ1Z(h1, τ2))rˆ1Y (h1, τ2) > −∆Y ,
{−1, 1}, otherwise,
(10)
and we define
pˆi1∆(h1) =
⋃
τ2∈F(pˆi2∆)
pˆi1∆(h1, τ2). (11)
Thus, pˆi1∆ is a set-valued decision rule that assigns a single treatment if only that treatment leads to
an (estimated) expected clinically meaningful improvement on one or both outcomes and does not lead to a
clinically meaningful loss in either outcome across all the treatment rules in F(pˆi2∆) that a clinician might
consider at the second stage. Alternatives to this definition of pˆi1∆ are discussed in Section 6.
4.1 Computation
Computing pˆi1∆(h1) requires solving what appears to be a difficult enumeration problem. Nevertheless, exact
computation of pˆi1∆(h1) is possible and (11) can be solved quickly when p2 is small.
First, note that if τ2 and τ
′
2 are decision rules at the second stage that agree on the observed data D, that
is, τ2(h2i) = τ
′
2(h2i) for all values h2i in D, then ψˆ1Y (τ2) = ψˆ1Y (τ ′2) and ψˆ1Z(τ2) = ψˆ1Z(τ ′2). It follows that
pˆi1∆(h1, τ2) = pˆi1∆(h1, τ
′
2) ∀h1 ∈ H1. Thus, if we consider a finite subset F˜(pˆi2∆) of F(pˆi2∆) that contains
one decision rule for each possible “labeling” of the stage 2 histories contained in D, then we have
pˆi1∆(h1) =
⋃
τ2∈F(pˆi2∆)
pˆi1∆(h1, τ2) =
⋃
τ2∈F˜(pˆi2∆)
pˆi1∆(h1, τ2). (12)
14
We use the term “labeling” by analogy with classification: histories at stage 2 are given a binary “label” by
τ2 which is either 1 or −1. Rather than taking a union over the potentially uncountable F(pˆi2∆), we will
enumerate the finite set of all feasible labelings of the observed data, place a corresponding τ2 for each one
into the set F˜(pˆi2∆), and take the union over F˜(pˆi2∆) instead.
We say that a labeling `i, i = 1, . . . , n is compatible with a set-valued decision rule pˆi2∆ if `i ∈ pˆi2∆(h2,i), i =
1, . . . , n and feasible if it can be induced by a feasible decision rule τ2 ∈ F(pˆi2∆). Equivalently, the labeling
is feasible if it is both compatible with pˆi2∆ and if the two sets {h2i|`i = 1} and {h2i|`i = −1} are linearly
separable in Rp2 . Our algorithm for computing F˜(pˆi2∆) works by specifying a mixed integer linear program
with indicator constraints2 whose feasible solutions correspond to the linearly separable labelings of D that
are compatible with pˆi2∆.
First, we note that determining whether or not a given labeling `i, i ∈ 1, . . . , n is compatible with pˆi2∆ is
equivalent to checking the following set of constraints:
∃ψ2 s.t. `ihᵀ2,iψ2 ≥ 1 ∀i ∈ 1, . . . , n (13)
Given a particular labeling, the existence of a ψ2 that satisfies (13) can be proven or disproven in polynomial
time using a linear program solver (see, for example, Megiddo 1987 and references therein). The existence of
such a ψ2 implies a compatible τ given by τ(h2) = sgn(h
ᵀ
2ψ2) that produces labeling `1, . . . , `n when applied
to the stage 2 data.
To find all possible feasible labelings, we formulate the following mixed integer linear program with
indicator constraints
min
`1,`2,...,`n,ψ2
f(`1, `2, ..., `n, ψ2)
s.t. ∀i ∈ 1, . . . , n, `i ∈ {−1, 1}
hᵀ2,2,iψ2 ≥ 1 if `i = 1
hᵀ2,2,iψ2 ≤ −1 if `i = −1
ψ2 ∈ Rp2
2In the field of mathematical programming, the term “indicator constraint” is used for a constraint that is only enforced when
a variable takes on a particular value, e.g. when an indicator variable is 1. (A better term might be “conditional constraint.”)
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and find all feasible solutions. Note that exactly one of the constraints involving h2i is enforced for a
particular value of `i. We present the feasibility problem as a minimization because it is the natural form
for modern optimization software packages like CPLEX, which are capable of handling both the integer
constraints on `i and the indicator constraints on ψ2. Note that if we simply want to recover the feasible
`i then the choice of f does not matter, and we may choose f = 0 for simplicity and efficiency in practice.
CPLEX is capable of enumerating all feasible solutions efficiently (the examples considered in this paper
take less than one minute to run on a laptop with 8GB DDR3 RAM and a 2.67GHz dual core processor). If
we wanted to also recover the maximum margin separators for the feasible labelings, for example, we could
use the quadratic objective f = ‖ψ2‖2.
Let F˜(pˆi2∆) denote the collection of feasible decision rules defined by sgn(hᵀ2,2ψ2) for each feasible ψ2.
Then for any h1 ∈ Rp1
pˆi1∆(h1) =
⋃
τ2∈F˜(pˆi2∆)
pˆi1∆(h1, τ2). (14)
Note that F˜(pˆi2∆) does not depend on the vector h1 and hence only needs to be computed once for a given
dataset.
5 Examples
5.1 Nefazodone study
In this section we illustrate the estimation of a static set-valued decision rule for a single decision point with
two competing outcomes. The data are from the initial (12 week) phase of a multicenter longitudinal study
comparing three treatment combinations for chronic depression [Keller et al., 2000]. A total of 681 subjects
were randomly assigned with equal probability to nefazodone only (Drug), cognitive behavioral therapy only
(CBT), or a combination of the two (Drug+CBT). CBT requires up to twice-weekly on-site visits to the clinic
and thus, relative to Drug, CBT represents a substantial time and monetary burden on patients. Hence,
an important question is which patients are likely to benefit from CBT beyond Drug only on one or more
outcomes. To focus on this question and simplify our exposition, we consider only the treatments Drug and
Drug+CBT.
The primary outcome for the study was depression as measured by the 24-item Hamilton Rating Scale
for Depression (HRSD) where lower scores signify a healthier state. However, nefazodone is associated with
fatigue and lack of physical coordination and thus physical functioning represents an important competing
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outcome to depression. Physical functioning is quantified in this study using the physical functioning factor
score in the Medical Outcomes Study 36-Item Short Form Health Survey (PF). PF was measured at baseline
and at 12 weeks and we let Z denote the 12 week measurement. HRSD was measured at baseline and weeks
1, 2, 3, 4, 6, 8, 10, and 12. Let Yj denote a patients HRSD at week j. To reduce variability and to capture
patient improvement over the duration of the study, we define the outcome Y to be the least squares slope
of Y0, Y1, . . . , Y12 on the observation times j = 0, 1, . . . , 12. For patients missing HRSD measurements Y was
computed using the least squares slope of the observed measurements on the observed measurement times.
Of the 681 patients enrolled in the study, 226 were assigned to Drug while 227 were assigned to
Drug+CBT. PF was not measured on all patients so we use a subset of 164 patients assigned to Drug
and 172 patients with Drug+CBT with complete PF measurements. There was no missingness in baseline
covariates. In order to estimate the ideal decision rule derived in Section 3, we modeled the conditional
expectations E(Y |H = h,A = a) and E(Z|H = h,A = a) using the working models of the form given in (2)
and (3). There were a large number of covariates collected at baseline and we constructed our models based
on clinician input and exploratory data analysis. Typical regression diagnostics for linear regression [e.g.,
Cook and Weisberg, 1999] suggest that the models fit the data reasonably well. The covariates included
in the model for depression (outcome Y ) were the subject’s baseline Hamilton depression score (hamd);
role functioning physical factor score (a measure of the ability to perform physical related roles) (rolfun);
the assigned treatment (Drug was coded as -1 and Drug+CBT was coded as 1)(trt); and the interactions
trt*hamd and trt*rolfun. The covariates included in the physical functioning model were the subject’s
baseline physical functioning factor score (phyfun); patient gender (gender); sleep score (a measure of the
subject’s quality of sleep) (slpsc); overall general health perception score (genhel); role functioning score
(rolfun); age of onset of depression (mdage); presence of dysthemia (dyst); the assigned treatment (trt),
and the interactions trt*slpsc and trt*phyfun. Tables 1 and 2 display the fitted parameters for each
model.
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Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.2867 0.2158 1.33 0.1848
hamd 0.0325 0.0074 4.41 0.0000
rolfun -0.0009 0.0009 -1.01 0.3135
trt 0.1133 0.2158 0.53 0.5998
rolfun*trt 0.0018 0.0009 2.01 0.0452
hamd*trt 0.0011 0.0074 0.14 0.8858
Table 2: Summary of the fitted coefficients for depression model.
Estimate Std. Error t value Pr(>|t|)
(Intercept) 35.6607 4.8319 7.38 0.0000
gender -3.4435 1.5851 -2.17 0.0305
slpsc -0.0979 0.3481 -0.28 0.7786
phyfun 0.6198 0.0442 14.01 0.0000
genhel 0.1384 0.0413 3.35 0.0009
rolfun -0.0436 0.0206 -2.12 0.0349
mdage -0.1236 0.0583 -2.12 0.0347
dyst -3.8610 1.4859 -2.60 0.0098
trt 11.3895 3.8200 2.98 0.0031
slpsc*trt -0.8737 0.3443 -2.54 0.0116
phyfun*trt -0.0714 0.0365 -1.96 0.0511
Table 3: Summary of the fitted coefficients for physical functioning model.
In what follows we use ∆Y = .25 as a clinically meaningful difference for depression which translates into
a change of 4 units in a subject’s depression score over 12 weeks. HRSD is typically categorized into one of
five severity categories, four units roughly corresponds to moving one of these categories. We use ∆Z = 5
which corresponds to a 5% change on the scale PF is measured. It is important to note that these thresholds
have been chosen here primarily for illustrative purposes. Using the foregoing values of ∆Y and ∆Z , we
estimated the ideal decisions using the methods described in Section 3. To get a sense of the estimated set-
valued decision rule we approximated the estimated decision rule with a decision tree. Figure 4 displays the
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estimated ideal decision rule as approximated using a decision tree. Note, ‘high’,‘medium’ and ‘low’ values
were used instead of actual scores for plot clarity. Drug+CBT was always included in the set of recommended
treatments but for patients with low role functioning (rolfun) and low sleep scores (slpsc) there a negligible
treatment effect and Drug only may not be significantly different than Drug+CBT. Another useful display
of the set valued decision rule is to plot the estimated contrasts 2hT1,2ψˆY and 2h
T
1,2ψˆZ against each other and
to label the regions where the decision rule changes. This plot is shown in Figure 5.
Figure 4: A decision tree approximating the estimated ideal decision rule for the nefazodone study. The
leaves of the tree indicate the optimal treatment (1 for combination or -1 for drug) along with which outcome
(Y for depression or Z for physical functioning) the subject would see a clinically significant change in.
The primary analysis of the depression study found that the Drug+CBT was the most effective [Keller
et al., 2000] and the results in Figures 4 and 5 are consistent with this analysis. Almost always, the com-
bination treatment was recommend when considering depression and physical functioning as the competing
outcomes. As seen in Figure 4, only 5 subjects were assigned the drug treatment as their ideal treatment
with the remaining subjects being assigned either the combination treatment or no treatment. Because of
this, the decision tree in Figure 4 only assigns future subjects to the combination treatment or no treatment.
Additionally, it provides information about which outcome the subject would likely see clinically significant
results in if they were to follow these decisions. Note that the slpsc*trt and rolfun*trt interactions were
both found significant in the models and it is at these variables where the splits in the tree were made.
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Figure 5: Diagram showing how the output of piIdeal(h) depends on ∆Y and ∆Z , and on the location of the
point (rY (h), rZ(h)).
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5.2 CATIE
We now consider the application of our method to data from the Clinical Antipsychotic Trials of Interven-
tion Effectiveness (CATIE) Schizophrenia study. The CATIE study was designed to compare sequences of
antipsychotic drug treatments for the care of schizophrenia patients. The full study design is quite complex
[Stroup et al., 2003]; we will make several simplifications in order to more clearly illustrate the potential of
the method presented here. CATIE was an 18-month sequential randomized trial that was divided into two
main phases of treatment. Upon entry into the study, most patients began “Phase 1,” in which they were
randomized to one of five possible treatments with equal probability: olanzapine, risperidone, quetiapine,
ziprasidone, or perphenazine. As they progressed through the study, patients were given the opportunity
at each monthly visit to discontinue their Phase 1 treatment and begin “Phase 2” on a new treatment.
The set of possible Phase 2 treatments depended on the reason for discontinuing Phase 1 treatment. If the
Phase 1 treatment was deemed to produce unacceptable side-effects, they entered the tolerability arm and
their Phase 2 treatment was chosen uniformly randomly from the set {olanzapine, risperidone, quetiapine,
ziprasidone}. If the Phase 1 treatment was deemed to be ineffective at reducing symptoms, they entered the
efficacy arm and their Phase 2 treatment was chosen randomly as follows: clozapine with probability 1/2,
or uniformly randomly from the set {olanzapine, risperidone, quetiapine} with probability 1/2.
Although CATIE was designed to compare several treatments within each arm, there are natural group-
ings at each stage that allow us to collapse the data in a meaningful way so that we consider only binary
treatments and we can therefore directly apply our method as described. In the Phase 2 Tolerability arm, it
is natural to compare olanzapine against the other three drugs since it is known a priori to be efficacious, but
is also known to cause significant weight gain as a side-effect. In the Phase 2 Efficacy arm, it is natural to
compare clozapine against the rest of the potential treatments, both because the randomization probabilities
called for having 50% of patients in that arm on clozapine, and because clozapine is substantively different
from the other three drugs: it is known to be highly effective at controlling symptoms, but it is also known
to have significant side-effects and its safe administration requires very close patient monitoring. In Phase
1, it is natural to compare perphenazine, the only typical antipsychotic, against the other four drugs which
are atypical antipsychotics. (This comparison of typical-versus-atypical was in fact an important goal of the
CATIE study.)
For our first outcome, Y , we use the Positive and Negative Syndrome Scale (PANSS) which is a numerical
representation of the level of psychotic symptoms experienced by a patient [Kay et al., 1987]. A higher
value of PANSS reflects the presence of more severe symptoms. PANSS is a well-established measure that
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we have used in previous work on the CATIE study [Shortreed et al., 2011]. Since having larger PANSS is
worse, for our first outcome Y we use 100 minus the percentile of a patient’s PANSS at the end of their time
in the study. We use the distribution of PANSS at the beginning of the study as the reference distribution
for the percentile.
For our second outcome, we use Body Mass Index (BMI), a measure of obesity. Weight gain is an
important and problematic side-effect of many antipsychotic drugs [Allison et al., 1999]. Since in this
population having a larger BMI is worse, for our second outcome Z we use 100 minus the percentile of a
patient’s BMI at the end of their time in the study. Again, we use the distribution of BMI at the beginning
of the study as the reference distribution for the percentile.
In all of our models, we include two baseline covariates. The first, td, is a dummy variable indicating if a
patient has “tardive dyskinesia,” which is a motor side-effect that can be caused by previous treatment. The
second, exacer, is a dummy variable indicating that a patient has been recently hospitalized, thus indicating
an exacerbation of his or her condition. These do not interact with treatment.
For our covariates h2 that interact with treatment, we choose the patients most recently recorded PANSS
score percentile in our model for PANSS, and the most recently recorded BMI percentile in our model for
BMI. These percentiles were shifted by −50 so that a patient with at the median has h2 = 0. This was
done so that in each model, the coefficient for the main effect of treatment can be directly interpreted as
the treatment effect for a patient with median PANSS (resp. BMI). Treatments were coded 1,−1. For both
outcomes we chose 5 percentile points as our indifference range, so ∆Y = ∆Z = 5.
5.2.1 Phase 2 Tolerability
Estimate Std. Error t value Pr(>|t|)
(Intercept) 55.6979 2.0335 27.3898 0.0000
td -3.5892 3.8915 -0.9223 0.3571
exacer 0.8697 3.2249 0.2697 0.7876
panss 0.6213 0.0581 10.7015 0.0000
olan 3.2705 1.6885 1.9370 0.0054
panss*olan -0.0136 0.0583 -0.2326 0.8162
Table 4: Summary of the fitted coefficients for PANSS outcome, Phase 2 Tolerability arm. N = 295.
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Figure 6: Diagram showing how the output of piIdeal(h) depends on ∆Y and ∆Z , and on the location of the
point (rY (h), rZ(h)), for the Phase 2 Tolerability arm.
Estimate Std. Error t value Pr(>|t|)
(Intercept) 47.7079 0.8138 58.6223 0.0000
td 0.7497 1.5619 0.4800 0.6316
exacer -0.9157 1.2952 -0.7070 0.4801
bmi 0.9166 0.0228 40.1616 0.0000
olan -3.9836 0.6708 -5.9383 0.0000
bmi*olan -0.0124 0.0228 -0.5464 0.5852
Table 5: Summary of the fitted coefficients for BMI outcome, Phase 2 Tolerability arm. N = 295.
Tables 4 and 5 show the models estimated from the Phase 2 tolerability data. As expected, olanzapine
appears to be benificial if one considers the PANSS (Y ) outcome, but detrimental if one considers the BMI
(Z) outcome. This is borne out in Figure 6, where we see that the predictions of (rY , rZ) for all of the patient
histories in our dataset fall in the lower-right region of the plot, where both treatments are recommended
because they conflict with each other according to the two outcomes.
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5.2.2 Phase 2 Efficacy
Estimate Std. Error t value Pr(>|t|)
(Intercept) 54.7307 4.4225 12.3756 0.0000
td 1.1844 7.9962 0.1481 0.8828
exacer -3.0871 6.9329 -0.4453 0.6580
panss 0.6363 0.1299 4.898 0.0000
cloz 9.2920 3.7722 2.463 0.0173
panss*cloz 0.0220 0.1312 0.1673 0.8678
Table 6: Summary of the fitted coefficients for PANSS outcome, Phase 2 Efficacy arm.
Estimate Std. Error t value Pr(>|t|)
(Intercept) 50.7367 1.7384 29.1863 0.0000
td -5.2649 3.0542 -1.7238 0.0916
exacer -2.1386 2.8634 -0.7469 0.4586
bmi 0.9277 0.0507 18.2857 0.0000
cloz -1.1109 1.3582 -0.8179 0.4173
bmi*cloz -0.0592 0.0525 -1.1272 0.2650
Table 7: Summary of the fitted coefficients for BMI outcome, Phase 2 Efficacy arm. N = 56
Tables 6 and 7 show the models estimated from the Phase 2 efficacy data. As expected, clozapine appears to
be beneficial if one considers the PANSS (Y ) outcome. Furthermore, there is weak evidence that clozapine
is detrimental if one considers the BMI (Z) outcome. This is borne out in Figure 7, where we see that the
predictions of (rY , rZ) for all of the patient histories in our dataset are to the right of rY = ∆Y , indicating
that clozapine is predicted to be the better choice for all patients in the dataset when considering only
the PANSS outcome. Furthermore, for most of these, clozapine is not significantly worse than the other
(aggregate) treatment according to BMI; thus for most of the histories only clozapine (i.e. {1} would be
recommended. We found that for patients with a BMI covariate greater than about 24 (i.e. those among the
top best 25 percent according to BMI3), however, clozapine is predicted to perform clinically significantly
3Recall the negative coding (higher percentiles are better) and the shift by 50: It is the patients whose BMI is better than
the 74th percentile who are recommended both treatments {−1, 1}.
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Figure 7: Diagram showing how the output of piIdeal(h) depends on ∆Y and ∆Z , and on the location of the
point (rY (h), rZ(h)), for the Phase 2 Efficacy arm. N = 56.
worse according to the BMI outcome, and both treatments (i.e. {−1, 1}) would be recommended for these
patients.
5.2.3 Phase 1
Estimate Std. Error t value Pr(>|t|)
(Intercept) 57.3576 1.0382 55.2486 0.0000
td -5.8840 2.0415 -2.8823 0.0004
exacer 1.1234 1.6471 0.6821 0.4954
panss 0.5332 0.0318 16.7574 0.0000
perp -2.6691 0.9505 -2.8081 0.0051
panss*perp 0.0778 0.0317 2.4531 0.0143
Table 8: Example summary of the fitted coefficients for PANSS outcome, Phase 1, based on a randomly
chosen feasible decision rule for Phase 2. N = 974
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Estimate Std. Error t value Pr(>|t|)
(Intercept) 49.0622 0.5084 96.5089 0.0000
td 1.2004 1.0069 1.1922 0.2335
exacer -2.7812 0.8175 -3.4022 0.0007
bmi 0.9134 0.0163 55.2402 0.0000
perp 1.8266 0.4659 3.9197 0.0001
bmi*perp -0.0250 0.0163 -1.5388 0.1242
Table 9: Example summary of the fitted coefficients for BMI outcome, based on a randomly chosen feasible
decision rule for Phase 2. N = 974.
We now consider Phase 1. Recall that given any history h1 at Phase 1, our predicted values (rY , rZ) for
that history depend not only on the history itself but on the future decision rule that will be followed
subsequently. For illustrative purposes, Tables 8 and 9 show the models estimated from the Phase 1 data
assuming a particular feasible decision rule for Phase 2 chosen from the 61, 659 feasible Phase 2 decision rules
enumerated by our algorithm. (The estimated coefficients would be different had we used a different Phase
2 decision rule.) For this particular future decision rule, perphenazine performs somewhat worse according
to PANSS than the atypical antipsychotics, and somewhat better according to BMI.
Whereas for the Phase 2 analyses we showed plots of different (rY , rZ) for different histories, for Phase
1, we will show different (rY , rZ) for a fixed history at Phase 1 as we vary the Phase 2 decision rule. Recall
that our treatment recommendation for Phase 1 is the union over all feasible future decision rules of the
treatments recommended for each future decision rule. Figure 8 shows the possible values of (rY , rZ). From
Figure 8, we can see that for some future decision rules only treatment −1 is recommended, but for others
the set {−1, 1} is recommended. Taking the union, we recommend the set {−1, 1} for this history at Phase
1.
6 Discussion
We proposed set-valued dynamic treatment regimes as a method for adapting treatment recommendations
to the evolving health status of a patient in the presence of competing outcomes. Our proposed methodology
deals with the reality that there is typically no universally good treatment for chronic illnesses like depres-
sion or schizophrenia by identifying when a trade-off between effectiveness and side-effects must be made.
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Figure 8: Diagram showing how the output of piIdeal(h) depends on ∆Y and ∆Z , and on the location of the
point (rY (h), rZ(h)), for Phase 1, at history panss = −25.5,bmi = −15.6).
Although computation of the set-valued dynamic treatment regimes requires solving a difficult enumeration
problem, we offered an efficient algorithm that makes use of existing linear mixed integer programming soft-
ware packages. We demonstrated the use of our method using data from one-stage and two-stage randomized
clinical trials.
Our proposed methodology avoids the construction of composite outcomes, a process which may be
undesirable: constructing a composite outcome requires combining outcomes that are on different scales, the
‘optimal trade-off’ between two (or more) outcomes is likely to be patient-specific, and the assumption that
a linear trade-off is sufficient to describe all possible patient preferences may be unrealistic.
There are a number of directions in which this work can be extended. The appendix provides an extension
to the case with two decision points but an arbitrary number of treatment choices available at each stage.
Interestingly, our enumeration problem is closely related to transductive learning, a classification problem
setting where only a subset of the available training data is labeled, and the task is to predict labels at the
unlabeled points in the training data. By finding a minimum-norm solution for ψ subject to our constraints,
we could produce the transductive labeling that induces the maximum margin linear separator. In essence,
our algorithm would then correspond to a linear separable transductive support vector machine (SVM)
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[Cortes and Vapnik, 1995]. This observation leads to a possible criterion for evaluating feasible decision
rules: we hypothesize that the greater the induced margin, the more “intuitive” the decision rule, because
large-margin decision rules avoid giving very similar patients different treatments. If the number of feasible
future decision rules becomes impractically large, we may wish to keep only the most “separable” ones when
computing the union at the first stage. We are currently pursuing this line of research.
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A Multiple Treatments
To develop our method for the binary treatment case, we considered working models of the form Qt(ht, at) =
hᵀt,1βt+ath
ᵀ
t,2ψt, and we defined our estimated optimal treatment for history ht to be pˆit(ht) = arg maxat∈{−1,1} Qˆ(ht, at).
If there are more than two levels of treatment (suppose at belongs to a discrete set At) we define estimated
working models of the form
Qˆt(ht, at) = h
ᵀ
t,1βˆt + φ(at, ht,2)
ᵀψˆt (15)
30
where the vector-valued function φ describes an arbitrary encoding of at along with any desired interactions
between the encoding and ht,2. For example, if At = {1, 2, 3} and ht,2 is a scalar, we might use
φ(at, ht,2) =

(0, 0, 0, 0)ᵀ if at = 1
(1, 0, ht,2, 0)
ᵀ if at = 2
(0, 1, 0, ht,2)
ᵀ if at = 3
(16)
to produce a model that incorporates a main effect of treatment as well as an interaction between treatment
and ht,2. The choice of how to encode factors and interactions has been well-studied [Wu et al., 2000].
Regardless of the specific choice of encoding, our estimated DTR is pˆit(ht) = arg maxat∈At Qˆ(ht, at).
A.1 Producing the Set-Valued Decision Rule
In order to identify the set of treatments that should be recommended for a particular ht, we consider all
pairs of treatments and identify those which are never eliminated in any pairwise comparison according to our
definition of ‘clincial significance.’ Continuing our example, if for a particular ht we find that considering 1
and 2 recommends the set {1, 2} and that considering 1 and 3 recommends the set {1}, then we would include
treatment 1 in our recommended set for ht. Note that we can also infer that 3 would not be recommended,
since in a pairwise comparison with 1 it is eliminated.
A.2 Enumerating the Feasible Decision Rules
To construct the MIP describing the feasible decision rules, we introduce n × |At| indicator variables αi,j
that indicate whether pˆi(h
(i)
t ) = j or not. We then impose the following constraints:
∀i ∈ 1...n, j ∈ 1...|At|, αi,j ∈ {0, 1} (17)
∀i ∈ 1...n,
∑
j
αi,j = 1 (18)
∀i ∈ 1...n, ∀j ∈ 1...|At|, αi,j = 1 =⇒ ∀k 6= j, (φ(h(i)t , j)− φ(h(i)t , k))ᵀψ2 ≥ 1. (19)
Constraints (17) ensure that the indicator variables for the actions are binary. Constraints (18) ensure
that, for each example in our dataset, exactly one action indicator variable is on. The indicator constraints
in (19) ensure that if the indicator for action j is on for the ith example, then weights must satisfy j =
31
arg maxa φ(s
i, a)ᵀw. Note that the margin condition (i.e. having the constraint be ≥ 1 rather than ≥ 0)
avoids a degenerate solution with ψ2 = 0.
The above constraints ensure that the αi,j define a treatment rule that can be represented as an arg max
in the given covariate space. Imposing the additional constraint that the treatment rule defined is compatible
with a given set-valued treatment rule p˜i is now trivial:
∀i ∈ 1...n,
∑
j∈p˜i(h(i))
αi,j = 1. (20)
Constraints (20) ensure that the indicator that turns on for the ith example in the data must be one that
indicates an action already present in p˜i(h(i)).
Using the approaches developed in Sections A.1 and A.2, an estimation procedure analogous to that
described in Section 4 immediately follows.
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B Regression Diagnostics
B.1 Nefazodone study
Depression
Residuals:
Min 1Q Median 3Q Max
-2.25326 -0.35043 0.02561 0.46046 1.47199
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.2867221 0.2157694 1.329 0.1848
HAMDTOT 0.0324713 0.0073585 4.413 1.38e-05 ***
ROLFUN -0.0009138 0.0009052 -1.009 0.3135
RAND 0.1133281 0.2157694 0.525 0.5998
ROLFUN:RAND 0.0018196 0.0009052 2.010 0.0452 *
HAMDTOT:RAND 0.0010579 0.0073585 0.144 0.8858
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Residual standard error: 0.6544 on 330 degrees of freedom
Multiple R-squared: 0.1969,Adjusted R-squared: 0.1847
F-statistic: 16.18 on 5 and 330 DF, p-value: 2.835e-14
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Physical Functioning
Residuals:
Min 1Q Median 3Q Max
-43.741 -5.730 1.100 6.801 48.197
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 35.66068 4.83187 7.380 1.34e-12 ***
GENDER2 -3.44352 1.58505 -2.172 0.030543 *
SLPSC1 -0.09793 0.34809 -0.281 0.778627
PHYFUN 0.61981 0.04425 14.009 < 2e-16 ***
GENHEL 0.13838 0.04132 3.349 0.000906 ***
ROLFUN -0.04361 0.02059 -2.118 0.034945 *
MD_AGE -0.12357 0.05826 -2.121 0.034682 *
DYST_YES -3.86101 1.48587 -2.598 0.009792 **
RAND 11.38947 3.82004 2.982 0.003086 **
34
SLPSC1:RAND -0.87366 0.34430 -2.538 0.011633 *
PHYFUN:RAND -0.07143 0.03648 -1.958 0.051116 .
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Residual standard error: 13.22 on 324 degrees of freedom
(1 observation deleted due to missingness)
Multiple R-squared: 0.5556,Adjusted R-squared: 0.5419
F-statistic: 40.51 on 10 and 324 DF, p-value: < 2.2e-16
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B.2 CATIE
Note that at Phase 1 the regression estimators are non-regular, and that inference in this setting requires
additional care as many standard methods are not valid [Laber et al., 2011]. Nonetheless we include the
following standard regression diagnostics to give a sense of model fit.
35
B.2.1 Phase 2 Tolerability: PANSS
Residuals:
Min 1Q Median 3Q Max
-73.323 -17.868 -0.176 17.801 72.125
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 55.69794 2.03353 27.390 <2e-16 ***
TD -3.58917 3.89155 -0.922 0.3571
EXACER 0.86974 3.22493 0.270 0.7876
PANSS 0.62132 0.05806 10.702 <2e-16 ***
OLAN 3.27049 1.68846 1.937 0.0537 .
PANSS:OLAN -0.01356 0.05829 -0.233 0.8162
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Residual standard error: 24.47 on 289 degrees of freedom
Multiple R-squared: 0.3613,Adjusted R-squared: 0.3503
F-statistic: 32.7 on 5 and 289 DF, p-value: < 2.2e-16
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B.2.2 Phase 2 Tolerability: BMI
Residuals:
36
Min 1Q Median 3Q Max
-38.343 -4.787 -0.097 4.886 54.400
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 47.70789 0.81382 58.622 < 2e-16 ***
TD 0.74972 1.56186 0.480 0.632
EXACER -0.91572 1.29519 -0.707 0.480
BMI 0.91663 0.02282 40.162 < 2e-16 ***
OLAN -3.98360 0.67083 -5.938 8.25e-09 ***
BMI:OLAN -0.01245 0.02278 -0.546 0.585
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Residual standard error: 9.822 on 289 degrees of freedom
Multiple R-squared: 0.8765,Adjusted R-squared: 0.8744
F-statistic: 410.4 on 5 and 289 DF, p-value: < 2.2e-16
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B.2.3 Phase 2 Efficacy: PANSS
Residuals:
Min 1Q Median 3Q Max
-56.634 -15.947 -3.404 13.906 55.476
37
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 54.73068 4.42248 12.376 < 2e-16 ***
TD 1.18442 7.99619 0.148 0.8828
EXACER -3.08713 6.93291 -0.445 0.6580
PANSS 0.63633 0.12991 4.898 1.06e-05 ***
CLOZ 9.29195 3.77220 2.463 0.0173 *
PANSS:CLOZ 0.02196 0.13122 0.167 0.8678
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Residual standard error: 23.25 on 50 degrees of freedom
Multiple R-squared: 0.3782,Adjusted R-squared: 0.316
F-statistic: 6.082 on 5 and 50 DF, p-value: 0.0001793
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B.2.4 Phase 2 Efficacy: BMI
Residuals:
Min 1Q Median 3Q Max
-29.599 -3.581 1.045 5.294 18.453
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 50.73675 1.73837 29.186 <2e-16 ***
38
TD -5.26487 3.05415 -1.724 0.0909 .
EXACER -2.13863 2.86341 -0.747 0.4586
BMI 0.92768 0.05073 18.286 <2e-16 ***
CLOZ -1.11087 1.35825 -0.818 0.4173
BMI:CLOZ -0.05915 0.05248 -1.127 0.2650
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Residual standard error: 9.611 on 50 degrees of freedom
Multiple R-squared: 0.8846,Adjusted R-squared: 0.8731
F-statistic: 76.67 on 5 and 50 DF, p-value: < 2.2e-16
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B.2.5 Phase 1 PANSS - For a particular feasible Phase 2 decision rule
Residuals:
Min 1Q Median 3Q Max
-71.066 -13.755 0.302 15.982 66.103
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 57.35755 1.03817 55.249 < 2e-16 ***
TD -5.88398 2.04147 -2.882 0.00404 **
EXACER 1.12338 1.64705 0.682 0.49537
PANSS 0.53324 0.03182 16.757 < 2e-16 ***
39
PERP -2.66918 0.95054 -2.808 0.00508 **
PANSS:PERP 0.07784 0.03173 2.453 0.01434 *
---
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Residual standard error: 22.53 on 969 degrees of freedom
Multiple R-squared: 0.2854,Adjusted R-squared: 0.2817
F-statistic: 77.38 on 5 and 969 DF, p-value: < 2.2e-16
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Residuals vs Leverage
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B.2.6 Phase 1 BMI - For a particular feasible Phase 2 decision rule
Residuals:
Min 1Q Median 3Q Max
-59.767 -4.776 -0.307 5.721 48.318
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 49.06219 0.50837 96.509 < 2e-16 ***
TD 1.20040 1.00689 1.192 0.233479
EXACER -2.78115 0.81747 -3.402 0.000696 ***
BMI 0.90136 0.01632 55.240 < 2e-16 ***
PERP 1.82645 0.46597 3.920 9.49e-05 ***
BMI:PERP -0.02502 0.01626 -1.539 0.124167
---
40
Signif. codes: 0 *** 0.001 ** 0.01 * 0.05 . 0.1 1
Residual standard error: 11.13 on 969 degrees of freedom
Multiple R-squared: 0.8451,Adjusted R-squared: 0.8443
F-statistic: 1057 on 5 and 969 DF, p-value: < 2.2e-16
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Residuals vs Leverage
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